Neurocrine Biosciences CEO Gano Kyle received 8,117 shares at $0 per share on 2026-09-11, while 4,380 shares were forfeited at $156.22 per share. The transactions left Kyle with 154,728 shares, giving investors the reported post-transaction ownership figure.
Key Highlights
- Kyle’s ownership was listed at 155,722 shares after the award transactions.
- The forfeiture transactions covered 4,380 shares at $156.22 per share.
- Both transaction groups were recorded on 11 September 2026 under separate SEC transaction codes.
NEUROCRINE BIOSCIENCES INC (NASDAQ: NBIX) awarded Chief Executive Officer Gano Kyle 8,117 shares at $0 per share on 11 September 2026 across two transactions. The same date included the forfeiture of 4,380 shares at $156.22 per share. Kyle’s reported ownership after the forfeiture stood at 154,728 shares.
Award and Forfeiture Entries Set Out
The awarded shares were recorded under transaction code A. The entries covered two separate transactions and assigned the shares a price of $0 per share. Kyle’s ownership following those transactions was listed as 155,722 shares. The forfeited shares were recorded under transaction code F. The code applied to two transactions involving 4,380 shares valued at $156.22 per share. Kyle’s ownership following those entries was listed as 154,728 shares. The $0 valuation applies to the awarded shares, while the $156.22 valuation applies to the forfeited shares. Both transaction groups identify Kyle as Neurocrine Biosciences’ chief executive officer and carry the date 11 September 2026. The transaction codes used here mean: A denotes an award, grant, or other Acquisition from the company; F denotes shares withheld or delivered to cover taxes or an exercise price.
FAQs
Q: How many Neurocrine Biosciences shares was Gano Kyle awarded?
A: Gano Kyle was awarded 8,117 Neurocrine Biosciences shares at $0 per share. The award was recorded across two transactions dated 11 September 2026.
Q: How many shares did the Neurocrine CEO forfeit?
A: Gano Kyle forfeited a total of 4,380 Neurocrine Biosciences shares across two separate transactions at $156.22 per share. The Form 4 records those forfeitures on 11 September 2026 under SEC transaction code F.
Q: What was Gano Kyle’s Neurocrine Biosciences ownership afterward?
A: Kyle’s reported ownership after the forfeiture transactions was 154,728 Neurocrine Biosciences shares. Ownership after the award transactions was listed at 155,722 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.